

MVK siRNA (m): sc-149725

BACKGROUND

Mevalonate kinase (MVK) is an early enzyme in isoprenoid and sterol synthesis. Mevalonate kinase catalyzes the ATP-dependent phosphorylation of mevalonic acid to form mevalonate 5-phosphate. Mevalonate is a key intermediate, and mevalonate kinase a key early enzyme, in isoprenoid and sterol synthesis. Deficiency in MVK activity contributes to mevalonic aciduria and hyperimmunoglobulinemia D/periodic fever syndrome (HIDS). Mevalonic acid accumulates because of failure of conversion to 5-phosphomevalonic acid, which is catalyzed by mevalonate kinase. Mevalonic acid is synthesized from 3-hydroxy-3-methylglutaryl-CoA, a reaction catalyzed by HMG-CoA reductase.

REFERENCES

1. Zheng, Q. 1994. On the exact hazard and survival functions of the MVK stochastic carcinogenesis model. *Risk Anal.* 14: 1081-1084.
2. Zheng, Q. 1995. On the MVK stochastic carcinogenesis model with Erlang distributed cell life lengths. *Risk Anal.* 15: 495-502.
3. Houten, S.M., Kuis, W., Duran, M., de Koning, T.J., van Royen-Kerkhof, A., Romeijn, G.J., Frenkel, J., Dorland, L., de Barse, M.M., Huijbers, W.A., Rijkers, G.T., Waterham, H.R., Wanders, R.J. and Poll-The, B.T. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. *Nat. Genet.* 22: 175-177.
4. Houten, S.M., Koster, J., Romeijn, G.J., Frenkel, J., Di Rocco, M., Caruso, U., Landrieu, P., Kelley, R.I., Kuis, W., Poll-The, B.T., Gibson, K.M., Wanders, R.J. and Waterham, H.R. 2001. Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinemia D and periodic fever syndrome. *Eur. J. Hum. Genet.* 9: 253-259.
5. Cuisset, L., Drenth, J.P., Simon, A., Vincent, M.F., van der Velde Visser, S., van der Meer, J.W., Grateau, G. and Delpech, M. 2001. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. *Eur. J. Hum. Genet.* 9: 260-266.
6. Fu, Z., Wang, M., Potter, D., Miziorko, H.M. and Kim, J.J. 2002. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. *J. Biol. Chem.* 277: 18134-18142.
7. Houten, S.M., van Woerden, C.S., Wijburg, F.A., Wanders, R.J. and Waterham, H.R. 2003. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with hyper-IgD and periodic fever syndrome, in the Netherlands. *Eur. J. Hum. Genet.* 11: 196-200.
8. Stojanov, S., Lohse, P., Lohse, P., Hoffmann, F., Renner, E.D., Zellerer, S., Kery, A., Shin, Y.S., Haas, D., Hoffmann, G.F. and Belohradsky, B.H. 2004. Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa. *Arthritis Rheum.* 50: 1951-1958.
9. LocusLink Report (LocusID: 4598). <http://www.ncbi.nlm.nih.gov/LocusLink/>

CHROMOSOMAL LOCATION

Genetic locus: Mvk (mouse) mapping to 5 F.

PRODUCT

MVK siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MVK shRNA Plasmid (m): sc-149725-SH and MVK shRNA (m) Lentiviral Particles: sc-149725-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MVK siRNA (m) is recommended for the inhibition of MVK expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MVK gene expression knockdown using RT-PCR Primer: MVK (m)-PR: sc-149725-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.